Skip to main content

Table 1 Baseline characteristics

From: Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus

 

DM population

p value

Non-DM population

p value

Complete revascularization (N = 893)

Incomplete revascularization (N = 1110)

Complete revascularization (n = 1833)

Incomplete revascularization (N = 1680)

Age, years

65.1 ± 9.4

65.2 ± 9.4

0.797

62.3 ± 10.6

65.1 ± 10.4

 < 0.001

Male

572 (64.1%)

725 (65.3%)

0.589

1265 (69.0%)

1179 (70.2%)

0.476

Body mass index, kg/m2

25.0 ± 3.1

24.9 ± 3.4

0.465

24.7 ± 3.0

24.7 ± 3.0

0.687

Hypertension

654 (73.2%)

848 (76.4%)

0.116

1070 (58.4%)

1051 (62.6%)

0.012

Dyslipidemia

538 (60.2%)

652 (58.7%)

0.524

965 (52.6%)

924 (55.0%)

0.173

Chronic kidney disease

310 (34.7%)

427 (38.5%)

0.092

422 (23.0%)

530 (31.5%)

 < 0.001

Peripheral vessel disease

15 (1.7%)

34 (3.0%)

0.065

19 (1.0%)

28 (1.7%)

0.140

Current smoker

181 (20.3%)

278 (25.0%)

0.140

496 (27.1%)

456 (27.1%)

0.986

Prior myocardial infarction

12 (1.3%)

22 (2.0%)

0.355

30 (1.6%)

49 (2.9%)

0.015

Prior stroke

93 (10.4%)

131 (11.8%)

0.364

111 (6.1%)

155 (9.2%)

 < 0.001

Family history of CAD

41 (4.6%)

71 (6.4%)

0.099

100 (5.5%)

112 (6.7%)

0.151

LVEF, %

60.9 ± 10.5

59.5 ± 11.1

0.006

62.2 ± 8.9

60.6 ± 10.2

 < 0.001

HbA1c, %

7.5 ± 1.6

7.5 ± 1.5

0.449

–

–

–

Presenting with cardiogenic shock

0 (0.0%)

7 (0.6%)

0.046

1 (0.1%)

4 (0.2%)

0.320

Presentations

 

 Unstable angina

431 (48.3%)

480 (43.2%)

0.118

925 (50.5%)

850 (50.6%)

0.069

 Stable angina

398 (44.6%)

530 (47.7%)

820 (44.7%)

719 (42.8%)

 Silent ischemia

64 (7.1%)

100 (9.1%)

88 (4.8%)

111 (6.6%)

Complexity of disease

 

 Left main disease

60 (6.7%)

86 (7.7%)

0.427

120 (6.5%)

133 (7.9%)

0.133

 Multivessel disease

447 (50.1%)

836 (75.3%)

 < 0.001

703 (38.4%)

1133 (67.4%)

 < 0.001

 At least 1 bifurcation

367 (41.1%)

500 (45.0%)

0.084

648 (35.4%)

774 (46.1%)

 < 0.001

 At least 1 long lesion

297 (33.3%)

465 (41.9%)

 < 0.001

438 (23.9%)

646 (38.5%)

 < 0.001

 At least 1 small vessel

473 (53.0%)

644 (58.0%)

0.027

684 (37.3%)

841 (50.1%)

 < 0.001

 Stent number per person

1.7 ± 1.0

1.8 ± 1.0

0.014

1.5 ± 0.8

1.8 ± 1.0

 < 0.001

 Total stent length, mm

42.0 ± 28.4

45.8 ± 28.1

0.003

35.1 ± 23.4

43.3 ± 27.5

 < 0.001

 Baseline SYNTAX score

10.8 ± 8.0

18.5 ± 8.8

 < 0.001

9.5 ± 7.0

17.4 ± 10.1

 < 0.001

 Residual SYNTAX score

0.0 ± 0.0

8.5 ± 6.2

 < 0.001

0.0 ± 0.0

7.6 ± 6.0

 < 0.001

Medication at discharge

 Statin

763 (85.4%)

929 (83.7%)

0.312

1615 (88.1%)

1472 (87.6%)

0.696

 ACE-I/ARB

574 (64.3%)

701 (63.2%)

0.636

1016 (55.4%)

981 (58.4%)

0.082

 Beta-blocker

467 (52.3%)

654 (58.9%)

0.003

939 (51.2%)

986 (58.7%)

 < 0.001

 Calcium-channel blocker

295 (33.0%)

336 (30.3%)

0.202

554 (30.2%)

493 (29.3%)

0.595

DM medication at discharge

 Insulin

128 (14.3%)

181 (16.3%)

0.249

–

–

–

 Sulfonylurea

245 (27.4%)

311 (28.0%)

0.811

–

–

–

 Metformin

298 (33.3%)

372 (33.5%)

0.984

–

–

–

 DPP4 inhibitor

116 (13.0%)

135 (12.2%)

0.625

–

–

–

 Alpha-glucosidase inhibitor

35 (3.9%)

57 (5.1%)

0.236

–

–

–

 TZD

21 (2.3%)

22 (2.0%)

0.680

–

–

–

  1. ACE-I/ARB, angiotensin converting enzyme inhibitor or angiotensin receptor blocker; CAD, coronary artery disease; DM, diabetes mellitus; DPP4, dipeptidyl peptidase 4; HbA1c, glycated hemoglobin; LVEF; left ventricular ejection fraction; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TZD, thiazolidinedione